Radius Health Inc. (NASDAQ:RDUS)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Group in a note issued to investors on Tuesday. They currently have a $46.00 price target on the biopharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential downside of 16.53% from the company’s previous close.

Several other brokerages also recently weighed in on RDUS. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Monday, August 8th. JPMorgan Chase & Co. restated a “buy” rating and set a $70.00 price target on shares of Radius Health in a research report on Friday, August 5th. Maxim Group downgraded shares of Radius Health from a “hold” rating to a “sell” rating and set a $24.00 price target on the stock. in a research report on Thursday, August 4th. Finally, Cowen and Company restated a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $61.73.

Radius Health (NASDAQ:RDUS) opened at 55.805 on Tuesday. The stock’s market cap is $2.40 billion. The company’s 50 day moving average is $54.45 and its 200 day moving average is $40.78. Radius Health has a 52 week low of $24.75 and a 52 week high of $77.10.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/jefferies-group-reiterates-hold-rating-for-radius-health-inc-rdus.html

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.06. During the same quarter in the previous year, the company posted ($0.61) EPS. Equities analysts predict that Radius Health will post ($3.95) earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors increased its position in Radius Health by 2.5% in the first quarter. BlackRock Fund Advisors now owns 1,367,137 shares of the biopharmaceutical company’s stock valued at $42,983,000 after buying an additional 33,421 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Radius Health by 0.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 807,600 shares of the biopharmaceutical company’s stock valued at $25,391,000 after buying an additional 3,792 shares during the period. State Street Corp increased its position in Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock valued at $49,938,000 after buying an additional 453,302 shares during the period. Bellevue Group AG purchased a new position in Radius Health during the first quarter valued at $1,258,000. Finally, JPMorgan Chase & Co. increased its position in Radius Health by 79.7% in the first quarter. JPMorgan Chase & Co. now owns 147,112 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 65,259 shares during the period. 99.91% of the stock is currently owned by institutional investors and hedge funds.

Radius Health Company Profile

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.